Blackstone life sciences announces collaboration to support moderna's influenza program

New york--(business wire)--blackstone (nyse:bx) announced today a new collaboration with moderna, inc. (nasdaq: mrna, “moderna”) through a development and commercialization funding agreement where funds managed by blackstone life sciences (“blackstone”) will provide up to $750 million to fund moderna's influenza (“flu”) program. “moderna has demonstrated a remarkable ability to impact human health through mrna vaccines targeting respiratory illnesses. this landmark collaboration is another exam.
MRNA Ratings Summary
MRNA Quant Ranking